Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.

ABSTRACT:

Background

The combination of statin therapy and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition markedly lowers low-density lipoprotein cholesterol (LDL-C) and reduces cardiovascular event rates. Whether residual inflammatory risk as measured by on-treatment high sensitivity C-reactive protein (hsCRP) remains an important clinical issue in such patients is uncertain.

Methods

We evaluated residual inflammatory risk among 9738 patients participating in the SPIRE-1 and SPIRE-2 cardiovascular outcomes trials (Studies of PCSK9 Inhibition and the Reduction in Vascular Events), who were receiving both statin therapy and bococizumab, according to on-treatment levels of hsCRP (hsCRP_OT) and LDL-C_OT measured 14 weeks after drug initiation. The pr

SUBMITTER: Pradhan AD 

PROVIDER: S-EPMC8108606 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature